Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.640
+0.147 (9.85%)
At close: Jul 31, 2026, 4:00 PM EDT
1.700
+0.060 (3.66%)
Pre-market: Aug 3, 2026, 5:56 AM EDT
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
1.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCLDI News
- 6 days ago - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewsWire
- 12 days ago - Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewsWire
- 13 days ago - Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - GlobeNewsWire
- 25 days ago - Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - GlobeNewsWire
- 6 weeks ago - Calidi receives pre-IND regulatory feedback from FDA for CLD-401 - TheFly
- 6 weeks ago - Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - GlobeNewsWire